ReviewExpert review of neurotherapeutics2009
Can peripheral leukocytes be used as Alzheimer's disease biomarkers?
Review in Expert review of neurotherapeutics, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 37 citations in OpenAlex.
- Associations between neutrophil-lymphocyte ratio and risk of cognitive impairment among Chinese older adults.BMC geriatrics · 2025Article
- Leukocyte surface biomarkers implicate deficits of innate immunity in sporadic Alzheimer's disease.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2023Article
- Machine Learning-Based Routine Laboratory Tests Predict One-Year Cognitive and Functional Decline in a Population Aged 75+ Years.Brain sciences · 2023Article
- Seven Tesla MRI in Alzheimer's disease research: State of the art and future directions: A narrative review.AIMS neuroscience · 2023Review
- Association of peripheral immunity with cognition, neuroimaging, and Alzheimer's pathology.Alzheimer's research & therapy · 2022Article
- Artificial intelligence and leukocyte epigenomics: Evaluation and prediction of late-onset Alzheimer's disease.PloS one · 2021Article
- Dysregulation of Systemic Immunity in Aging and Dementia.Frontiers in cellular neuroscience · 2021Review
- Peripheral immunophenotype in dementia with Lewy bodies and Alzheimer's disease: an observational clinical study.Journal of neurology, neurosurgery, and psychiatry · 2020Observational
- Single-cell peripheral immunoprofiling of Alzheimer's and Parkinson's diseases.Science advances · 2020Article
- Article
- Review
- Biomarkers: Our Path Towards a Cure for Alzheimer Disease.Biomarker insights · 2020Review
- Increased AβAlzheimer's research & therapy · 2017Article
- Traumatic Brain Injury Induces Genome-Wide Transcriptomic, Methylomic, and Network Perturbations in Brain and Blood Predicting Neurological Disorders.EBioMedicine · 2017Article
- Impairment of Several Immune Functions and Redox State in Blood Cells of Alzheimer's Disease Patients. Relevant Role of Neutrophils in Oxidative Stress.Frontiers in immunology · 2017Article
- Enrichment of risk SNPs in regulatory regions implicate diverse tissues in Parkinson's disease etiology.Scientific reports · 2016Article
- Article
- Leukocyte CCR2 expression is associated with mini-mental state examination score in older adults.Rejuvenation research · 2012Article
- Macrophages in Alzheimer's disease: the blood-borne identity.Journal of neural transmission (Vienna, Austria : 1996) · 2010Review
- Impact of the CD40-CD40L dyad in Alzheimer's disease.CNS & neurological disorders drug targets · 2010Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
Abstract
Alzheimer's disease (AD) is the leading cause of dementia in elderly populations throughout the world and its incidence is on the rise. Current clinical diagnosis of AD requires intensive examination that includes neuropsychological testing and costly brain imaging techniques, and a definitive diagnosis can only be made upon postmortem neuropathological examination. Additionally, antemortem clinical AD diagnosis is typically administered following onset of cognitive and behavioral symptoms. As these symptoms emerge relatively late in disease progression, therapeutic intervention occurs after significant neurodegeneration, thereby limiting efficacy. The identification of noninvasive diagnostic biomarkers of AD is becoming increasingly important to make diagnosis more widely available to clinics with limited access to neuropsychological testing or state-of-the-art brain imaging, reduce the cost of clinical diagnosis, provide a biological measure to track the course of therapeutic intervention, and most importantly, allow for earlier diagnosis--possibly even during the prodromal phase--with hopes of therapeutic intervention prior to appreciable neurodegeneration. Circulating leukocytes are attractive candidate AD biomarkers as they can be obtained in a minimally invasive manner and are easily analyzed by widely available flow cytometry techniques. In this review, we critically analyze the potential utility of peripheral leukocytes as biological markers for AD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.